Head-To-Head Comparison: Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) versus Tandem Diabetes Care (NASDAQ:TNDM)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Risk & Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Health Sciences Acquisitions Co. 2 and Tandem Diabetes Care, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	N/A
Tandem Diabetes Care	0	1	12	0	2.92

Tandem Diabetes Care has a consensus price target of $51.25, indicating a potential upside of 19.66%. Given Tandem Diabetes Care’s higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Health Sciences Acquisitions Co. 2.

Earnings & Valuation

This table compares Health Sciences Acquisitions Co. 2 and Tandem Diabetes Care’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Tandem Diabetes Care	$747.72 million	3.70	-$222.61 million	($2.17)	-19.74

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Tandem Diabetes Care.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Tandem Diabetes Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%

Institutional and Insider Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Health Sciences Acquisitions Co. 2 beats Tandem Diabetes Care on 6 of the 10 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.